|[May 23, 2014]
Batu Biologics Files Patent Covering its Proprietary Cancer Vaccine Targeting the Tumor Endothelium: Vallovax
SAN DIEGO --(Business Wire)--
Batu Biologics, a biopharmaceutical company focused on the development
and commercialization of cell therapies in the area of immune
modulation, is pleased to announce the filing of U.S. patent application
(61/987657) covering the composition and application of its flagship
product, Vallovax. The novel cancer vaccine is specifically formulated
to target the blood vessels that supply the tumor through induction of
tumor autoimmunity and immune stimulation.
"Angiogenesis has proven to be a key factor in the proliferation of
tumor cells within the host. Recent studies have revealed that without
the formation of new blood vessels, tumors are unable to receive the
blood supply they need to grow bigger than 1 to 2 mm in diameter,"
commented Andy J. Kim, Vice President of Scientific Research at Batu
Biologics. "Testimony to the power of angiogenic blockade is the drug
Avastin, which last quarter had sales of $1.6 billion1.
Unfortunately, existing drugs that block angiogenesis only target
specific pathways of this process, thus making them not universally
applicable. An example of this is the withdrawal of FDA approval for
treating metastatic breast cancer with Avastin in 20102. In
contrast to previous approaches targeting cancer endothelium, Vallovax
harnesses the power of the immune response, which allows for memory,
specificity, and adaptability."
The Vallovax platform builds upon the work of Dr. Valentine Govallo, who
recognized the placenta as one of the only natural systems that mimics
cancer through immune suppression, angiogenesis, and metastasis. The
"Govallo Vaccine", an uncharacterized placenta-based cancer
immunotherapy, exhibited remarkable rates of remission: 66.7% 10-year
survival rates for lung cancer patients3. Through recent
developments in cancer research, Batu Biologics has identified and
isolated the cells found in the "Govallo Vaccine" that combat
angiogenesis and metastasis in cancer and plan to file an
Investigational New Drug (IND) Application for non-small stage lung
cancer to the FDA in 2014.
"Our Team is motivated to bring novel therapeutics to the forefront of
medical research that use the power of the body's own immune system to
extend life expectancy," commented Samuel C. Wagner, President and CEO.
"Batu Biologics looks to pioneer the emerging field of cell therapy with
novel therapeutics that improve the quality of life for late-stage
patients with minimal toxic side-effects."
About Batu Biologics: Batu Biologics is a preclinical
biopharmaceutical company focusing on developing and commercializing
allogeneic cell therapies in the area of immune modulation. Our products
are centered around the idea of creating or breaking immune tolerance.
The company is currently in the preclinical stages of drug development
for its two flagship products: Immstem and Vallovax. Batu Biologics has
filed two provisional patents in the field of cancer immunotherapy and
plans to significantly expand its IP in 2014.
9255 Towne Centre Drive
Diego, CA (News - Alert) 92121
Janssen Research and Development
San Diego, CA 92121
Govallo, V. I. Immunology of Pregnancy and Cancer. Commack, NY:
Nova Science, 1993. 195-210.
[ Back To TMCnet.com's Homepage ]